Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

Back to Contracts

NonSurgical Debridement

Awarded

75A50126C00002Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Contract Value

$34,880,933

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Washington, DC, 20024, USA

Set-Aside

NONE

Awardee

VERICEL CORPORATION

Award Issued Date

04/01/2026, 12:00:00 AM UTC

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded

PostedApr 2

Award Notice

AwardedApr 1

Contract was awarded

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Contacts2 people available

OfficeWASHINGTON, DC, 20515, USA

Organization / AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Office AddressWASHINGTON, DC, 20515, USA

Contacts

Jonathan Gonzalez Contracting Officer

contact@example.gov

Yifan Yang

contact@example.gov

Full Description

Show more

This acquisition will allow BARDA to support procurement of an FDA-approved enzymatic debridement product and support development of a next generation product for increased preparedness value.

Similar Contracts

Same NAICS industry code

In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.

Rpo East (36C24E)

POSTED

about 9 hours ago

DEADLINE

AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.

Rpo East (36C24E)

POSTED

about 9 hours ago

DEADLINE

AJ12--Development/Production - Kidney GEC-Specific AAV Vector

Solicitation # 36C24E27Q0009

The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.

Rpo East (36C24E)

POSTED

about 9 hours ago

DEADLINE

MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.

National Institutes Of Health

POSTED

DEADLINE

Discovery Gateway to Reproductive Health InnovationThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to establish the Discovery Gateway to Reproductive Health Innovation. This initiative aims to create a comprehensive, open-access web-based visualization platform and knowledgebase to advance research on male and female reproductive health issues, including infertility, uterine fibroids, endometriosis, preeclampsia, and preterm birth. By integrating multi-omic, pharmacogenomic, and clinical data, the Gateway seeks to fill critical knowledge gaps and provide the biomedical community with shared infrastructure to identify biomarkers, drug targets, and disease mechanisms. The primary objective of this project is to catalyze the discovery of new treatments and cures while fostering public-private partnerships and the development of commercial products. This effort aligns with recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The opportunity is currently listed as a forecast, with administrative oversight provided by the Obstetric and Pediatric Pharmacology and Therapeutics Branch.

National Institutes Of Health

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting proposals for the Translational Centers Using Microphysiological Systems for Infectious Diseases under solicitation number RFA-AI-28-012. This initiative aims to establish a consortium of centers focused on refining and validating human tissue models to study infectious diseases and test medical interventions. By leveraging New Approach Methodologies, the program seeks to create in vitro systems that capture human variability and patient-specific characteristics, ultimately accelerating the development of safer treatments while reducing costs and the reliance on laboratory animals. The primary objective is to advance these microphysiological systems to a level of regulatory qualification that encourages adoption by product developers and ensures regulatory acceptance. Interested parties must submit their responses by the deadline of January 30, 2027. This federal opportunity specifically focuses on bridging the gap between current research and regulatory use for infectious disease models, though it is noted that clinical trials are not allowed under this specific funding mechanism.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Barley Net Blotch Initiative (BNBI) Program 2 – Host and pathogen genetics

Solicitation # PROC-9177507

The Grains Research and Development Corporation is seeking a partner to deliver Program 2 of the Barley Net Blotch Initiative, a five-year national effort to combat the significant economic threat of net blotch in Australian barley. This specific program focuses on host and pathogen genetics to fast-track the development of durable host resistance. Key objectives include providing breeder-deployable validated markers, characterizing resistance sources, conducting pathogenic genomics research, establishing a durability risk-assessment framework, and assessing the feasibility of genome-editing. This solicitation, identified as PROC-9177507, was posted on October 19, 2026, with a response deadline of March 4, 2027. The project is part of a broader strategy involving pathogen surveillance and integrated disease management to reduce the estimated 122 million dollar annual loss caused by yield decreases and grain quality downgrades. Performance of the contract will span multiple major Australian cities, including Canberra, Sydney, Melbourne, Adelaide, Perth, Brisbane, Darwin, and Hobart.

Grains Research and Development Corporation

POSTED

DEADLINE

Pre-Clinical Models of Infectious Diseases

Solicitation # 75N93027R00003

The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a ramp-on solicitation to award multiple IDIQ base contracts for the Preclinical Models of Infectious Diseases program. This initiative aims to expand the existing pool of contractors capable of developing and refining animal and animal replacement models to evaluate medical countermeasures, such as vaccines, therapeutics, and diagnostics. The program bridges the gap between in vitro testing and clinical evaluation, supporting regulatory submissions and the advancement of countermeasures against priority biodefense and emerging infectious agents. Successful offerors will be eligible to compete for task orders across four specific areas: Small Animal Models, Non-Human Primate Models, Animal Replacement and Non-traditional Animal Models, and the Generation and Distribution of Specialized Reagents. The scope of work emphasizes a wide array of pathogens, including pandemic-potential RNA viruses, antimicrobial-resistant infections, fungal diseases, and neglected tropical diseases. Proposals must be submitted electronically via the NIAID eCPS website, and applicants are required to have a valid NIH eRA Commons account for authentication and secure transmission.

National Institutes Of Health Niaid

POSTED

DEADLINE

in about 2 months

Alternative Protein Technologies for Military Field Feeding

Solicitation # W911QY27ALTPROTEINS

The US Army Combat Capabilities Development Command Soldier Center is seeking information from Massachusetts-based offerors to identify innovative alternative protein technologies for integration into military rations. The objective is to enhance food supply chain resilience and provide nutrient-dense, lightweight food options for warfighters. Areas of interest include fermentation and biomanufacturing processes, innovative product development for shelf-stable rations, consumer research for military acceptability, and the optional provision of GRAS-certified food samples. Specifically, the government is excluding any solutions involving cell-cultured, lab-grown meat, or insect proteins, focusing instead on technologies between TRL 4 and 6. This is a Sources Sought Announcement for market research purposes and not a formal solicitation or a promise of future funding. Interested parties must submit a BAA preproposal by November 23, 2026, including a technical approach, past performance, and a rough order of magnitude cost estimate. Submissions must be sent via email to the designated points of contact and include the offeror's business size, NAICS code, and CAGE code to verify their Massachusetts location.

W6QK Acc-Apg Natick

POSTED

DEADLINE

in about 1 month

More opportunities from Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Same awarding agency

PHI Cybersecurity ImplementationThe PHI Cybersecurity Implementation subcontract, issued by the Department of Health and Human Services under BARDA, focuses on establishing robust cybersecurity frameworks to protect sensitive patient health information for medical device projects. The scope of work includes the deployment of secure cloud infrastructure, encryption protocols, and secure data transmission systems to ensure safe medical device connectivity. The selected provider will deliver a comprehensive secure data management system and a final cybersecurity certification. Strict adherence to regulatory and technical standards is required, specifically HIPAA compliance, NIST SP 800-53, and HITRUST standards. This opportunity falls under NAICS code 541512 and is based in Washington. Interested parties must submit their responses by November 18, 2026.

Computer Systems Design Services

POSTED

DEADLINE

Medical Device Logistics and Surge DistributionThis subcontract for Medical Device Logistics and Surge Distribution supports prime contractors on BARDA medical device projects under the Department of Health and Human Services. The scope of work involves comprehensive warehousing, inventory management, and the rapid distribution of medical devices to hospitals and emergency departments. A critical component of the contract is the management of surge capacity for mass casualty events, utilizing climate-controlled facilities and medical-grade logistics software to ensure efficient delivery to designated care settings. To ensure safety and regulatory adherence, the provider must maintain strict compliance with Good Distribution Practice and HIPAA standards. The project is categorized under NAICS code 493110 and is centered in Washington. Interested parties should note the response deadline of November 18, 2026.

General Warehousing and Storage

POSTED

DEADLINE

Medical-Grade Raw Material SupplyThis subcontract, titled Medical-Grade Raw Material Supply, involves the sourcing, quality testing, and delivery of essential raw materials used in the production of trauma and fracture-management devices. Supporting prime contractors on BARDA medical device projects under the Department of Health and Human Services, the scope of work focuses on providing medical-grade titanium, stainless steel, and specialized polymers. To ensure safety and efficacy, the contractor must provide full material certifications and maintain strict compliance with medical grade purity standards. The project is associated with NAICS code 325211 and is designated for performance in Washington, with a response deadline set for November 18, 2026.

Plastics Material and Resin Manufacturing

POSTED

DEADLINE

Specialized Medical Component FabricationThis subcontract for Specialized Medical Component Fabrication involves the production of precision components for medical devices focused on trauma care and fracture stabilization. Working under prime contractors for BARDA projects within the Department of Health and Human Services, the selected provider will utilize precision CNC machining and molding to fabricate hardware from biocompatible polymers and medical-grade alloys. The contract requires strict adherence to FDA regulatory compliance and ISO 13485 certification to ensure the quality of the finished medical device components. Performance will take place in Washington, with a response deadline set for November 18, 2026.

Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

DEADLINE

Automated Ultrasound-Based, Super Intelligence (SI)-Enabled Fracture Detection

Solicitation # BARDA-FY27-10192026

The Center for Biomedical Advanced Research and Development Authority (BARDA) has issued Sources Sought Notice BARDA-FY27-10192026 to identify innovative medical countermeasure technologies for the rapid triage of musculoskeletal injuries, such as fractures and soft tissue injuries of extremities. This request for information is intended for planning and market research purposes to assess commercially available or nearing-commercial technologies that utilize Super Intelligence (SI) and machine learning for automated ultrasound-based fracture detection. The goal is to find standalone, point-of-care devices that can operate in emergency departments, urgent care centers, and austere field settings without relying on traditional imaging infrastructure like X-ray or CT scans. The desired technology must feature automated volumetric capture, 3D-rotatable modeling, and SI-enabled image processing that outperforms human imaging experts and has undergone FDA 510k clearance processes. BARDA is interested in ruggedized, portable units with sufficient battery life for disaster response, interoperability with electronic health record systems, and minimal training requirements for non-specialist operators. Potential acquisition strategies being explored include direct purchases, leases, or vendor-managed inventory arrangements. Interested small businesses and other than small business concerns under NAICS code 334510 must submit their capabilities statements by 1:00 p.m. Eastern Time on November 18, 2026. Submissions must include separate Technical and Business Representation sections, each limited to 10 pages in 12-point Times New Roman font, and be emailed to Justin Moore and Richard Hall. Responses should detail the company's manufacturing capabilities within the United States, regulatory maturity, supply chain resilience, and cybersecurity standards for handling sensitive patient health information.

Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

DEADLINE

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The primary objective is to maintain a permanent readiness posture and commercially sustainable warm-base production capacity for the rapid manufacture of vaccines, antigens, and adjuvants during public health emergencies. Selected contractors will be responsible for producing countermeasures against influenza and other viruses with pandemic potential, generating necessary analytical, nonclinical, clinical, and chemistry, manufacturing, and controls data for FDA submission, and preparing candidate vaccine viruses. To be eligible, offerors must demonstrate successful experience in influenza vaccine manufacturing, evidenced by holding a U.S. influenza vaccine license or having submitted a Biologics License Application to the FDA. The contract is structured as an IDIQ with a five-year base period and a five-year option, totaling a potential 120-month ordering period. Award decisions will be based on the Highest Technically Rated Offerors with a Fair and Reasonable Price methodology, with a critical requirement for offerors to achieve a High Confidence rating in capabilities. Key deliverables include the submission of comprehensive manufacturing and supply chain continuity plans, surge readiness assessments, and strict adherence to CGMP guidelines and ASPR security requirements. Performance is monitored through a BARDA dose tracker, and final acceptance is contingent upon the submission of final reports and verified temperature control documentation during delivery. Invoicing is conducted quarterly via the Department of Treasury Invoice Processing Platform.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 1 month

Vaccine Lot Production (Research, Investigational, and Commercial)This subcontract involves the production of influenza vaccine antigens and vaccines across research, investigational, and commercial bulk scales to support prime contractors on BARDA pandemic preparedness projects. The work is performed within cGMP compliant facilities to ensure all investigational and commercial lots meet strict regulatory alignment and quality standards. Managed by the Department of Health and Human Services under the Barda agency, the contract focuses on delivering bulk vaccine lots across three distinct production scales. The opportunity is categorized under NAICS code 325412, with a response deadline set for October 30, 2026, and performance based in Washington.

Pharmaceutical Preparation Manufacturing

POSTED

DEADLINE

cGMP Vaccine Seed Lot ManufacturingThis subcontract for cGMP Vaccine Seed Lot Manufacturing involves the production of yield-optimized Master Virus Seed, Working Virus Seed lots, or bacterial cell banks to support BARDA pandemic preparedness projects. The work is performed for prime contractors using qualified CVV reference strains within cGMP certified facilities that align with FDA-licensed vaccines or submitted BLAs. All seeds are characterized according to qualified internal standard operating procedures to ensure the delivery of certified lots. Managed by the Department of Health and Human Services under Barda, the contract falls under NAICS code 325412. The performance location is based in Washington, DC, with a response deadline of October 30, 2026.

Pharmaceutical Preparation Manufacturing

POSTED

DEADLINE

Candidate Vaccine Virus (CVV) Development & CharacterizationThis subcontract, titled Candidate Vaccine Virus Development and Characterization, supports BARDA pandemic preparedness projects by preparing and characterizing both non-GLP and GLP influenza Candidate Vaccine Viruses. The scope of work includes performing HA/NA sequencing, genetic stability testing, ferret pathogenicity, two-way antigenicity, HA titer, sterility, and exclusivity. Additionally, the contractor is responsible for conducting plaque assays and chicken embryo lethality for HPAI strains within a BSL-2 environment, culminating in the delivery of final reports and Certificates of Analysis or Compliance. Managed by the Department of Health and Human Services under the Barda - Aspr agency, the project is categorized under NAICS code 541714. The performance location is based in Washington, DC. The solicitation was posted on August 17, 2026, with a response deadline set for October 30, 2026.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Specialized Material Supply (Vials, Stoppers, Seals)This subcontract for Specialized Material Supply focuses on providing critical medical-grade components, including vials, stoppers, seals, and crimps, to support prime contractors on BARDA pandemic preparedness projects. The scope of work requires the delivery of physical inventory and the provision of comprehensive supply chain narratives that detail the country of origin and tariff exposure for all containment and closure materials. Managed by the Department of Health and Human Services under the agency Barda - Aspr / Daappo / Barda Dcma, the contract is categorized under NAICS code 326199. The place of performance is located in Washington, DC, with a response deadline set for October 30, 2026.

All Other Plastics Product Manufacturing

POSTED

DEADLINE

Labeling, Packaging, and Cold Chain StorageThis subcontract, managed by the Department of Health and Human Services under BARDA, focuses on providing essential labeling, packaging, and specialized stability storage for bulk and final vaccine products. The scope of work involves supporting prime contractors on pandemic preparedness projects by managing cold chain logistics and stability monitoring for commercial scale bulk antigens, final containers, and bulk adjuvants. The contractor is responsible for the delivery of packaged products and the provision of detailed stability reports. This opportunity is categorized under NAICS code 493110 and is based in Washington, DC. The response deadline for this requirement is October 30, 2026.

General Warehousing and Storage

POSTED

DEADLINE

Formulation, Filling, and Finishing ServicesThis subcontract for Formulation, Filling, and Finishing Services supports BARDA pandemic preparedness projects by providing final formulation and filling of antigens, adjuvants, or co-formulated products into final containers. The work is performed under cGMP compliant processes within sterile filling environments to ensure the delivery of high-quality filled vials and containers for prime contractors. The opportunity is managed by the Department of Health and Human Services under the Barda - Aspr / Daappo / Barda Dcma agency and is categorized under NAICS code 325412. The project is based in Washington, DC, with a response deadline of October 30, 2026.

Pharmaceutical Preparation Manufacturing

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS